iPLEDGE Login Guide: Systemic Failures, Compliance, and FDA Updates

The iPLEDGE program represents a critical safety framework in modern dermatological treatment, specifically designed to manage the risks associated with isotretinoin therapy for severe acne. However, this system, while protecting patient safety, is recognized as a major operational inefficiency costing dermatology practices significant time and contributing to high patient drop-off rates—with studies documenting that approximately 40% of isotretinoin prescriptions are denied annually due to iPLEDGE compliance failures, and research demonstrating that 36.8% of patients experience early treatment termination, often due to iPLEDGE-related logistics. Understanding how to navigate the iPLEDGE login portal and comply with its requirements is essential for patients, prescribers, and pharmacies involved in isotretinoin treatment. This comprehensive guide provides detailed, accurate information about the iPLEDGE login process, program requirements, and recent updates to ensure safe and compliant access to this life-changing medication.​

What is the iPLEDGE Program?

The iPLEDGE program is a mandatory Risk Evaluation and Mitigation Strategy (REMS) established by the U.S. Food and Drug Administration (FDA) to prevent fetal exposure to isotretinoin, a highly effective medication used to treat severe nodular acne. Launched on March 1, 2006, during the annual meeting of the American Academy of Dermatology, the program was created and is managed by the Isotretinoin Products Manufacturers Group (IPMG).​

Isotretinoin carries an extremely high risk of causing severe birth defects if taken during pregnancy, with risks approaching 60% for exposed fetuses. These birth defects can include skull abnormalities, facial dysmorphia, brain development issues, heart defects, eye and ear malformations, and severe intellectual disabilities. The iPLEDGE program aims to prevent pregnancies in patients taking isotretinoin and to prevent pregnant patients from taking isotretinoin through a computer-based risk management system that creates verifiable, traceable links between prescribers, patients, pharmacies, and wholesalers​.

Understanding Isotretinoin and Why iPLEDGE Exists

Isotretinoin, commonly known by the brand name Accutane, is the most effective treatment available for severe nodular acne that has not responded to other treatments, including antibiotics. The medication works by shrinking oil glands in the skin, preventing skin cells from sticking together and clogging pores, and reducing inflammation. Studies show that approximately 4 out of 5 patients who complete a typical 4-8 month course of isotretinoin treatment experience long-term improvement of their acne, with success rates approaching 90%.​

Unlike most other acne treatments that only work while being taken, isotretinoin can provide lasting results, often for life. This remarkable efficacy makes it the drug of last resort for severe acne that causes significant physical and psychological distress. However, the medication’s teratogenic properties—its ability to cause severe birth defects—necessitated the creation of a comprehensive risk management program.​

iPLEDGE Login Portal: How to Access Your Account

The iPLEDGE login portal is the central hub where prescribers, patients, and pharmacies access the system to fulfill program requirements. Understanding how to properly access and navigate this portal is crucial for uninterrupted treatment.

Accessing the iPLEDGE Website

To access the iPLEDGE login portal, visit the official website at ipledgeprogram.com. The homepagehomepage features an “Enroll | Login” button that directs users to the appropriate login page based on their role (patient, prescriber, or pharmacy)

Login Credentials and Initial Setup

For patients, your login credentials consist of a unique patient identification number and password. Your prescriber will provide you with a patient ID number and ID card during enrollment. Within 5-10 business days of registration, you should receive your password by mail. If you haven’t received your password or are a new user after December 13, 2021, you may need to create a new password using the system’s password creation feature.​

The system requires users to establish a “Date of Personal Significance” during initial setup—a memorable date that helps verify your identity if you need to reset your password or contact support. This date should be easy for you to remember but not easily guessed by others.​

Prescriber and Pharmacy Login

Prescribers access the system using their National Provider Identifier (NPI) number, username, and Date of Personal Significance. Pharmacies log in using their National Council for Prescription Drug Programs (NCPDP) number as their username. Both prescribers and pharmacies must complete registration and activation processes before they can prescribe or dispense isotretinoin​

Login Troubleshooting

If you encounter difficulties logging into the iPLEDGE portal, several resources are available. The website includes a “Forgot password?” link that allows you to reset your credentials. If the password reset email doesn’t arrive, check your spam folder and ensure your email address is correctly registered in the system.​

For persistent login issues, contact the iPLEDGE REMS Contact Center at 1-866-495-0654. The call center operates during normal business hours, with Monday being the busiest day due to high call volumes. To minimize wait times, consider calling later in the week. Some users have also reported success contacting customersupport@ipledgeremssupport.com for assistance.​

Prescribers experiencing difficulties can utilize a new feature that allows them to send login links directly to patients through the “Manage Patients” page by clicking the “SEND LOGIN LINK” button. This functionality helps patients who haven’t accessed the system or are having trouble logging in.​

Patient Categories and Requirements

As of December 13, 2021, the iPLEDGE program simplified patient risk categories from three options to two: patients who can get pregnant and patients who cannot get pregnant. This gender-neutral terminology replaced the previous categories of females of childbearing potential, females not of childbearing potential, and males.​

Patients Who Can Get Pregnant

This category includes anyone assigned female at birth who has the potential for pregnancy, regardless of gender identity. Patients in this category face more stringent requirements due to the severe risk of birth defects.​

Requirements include:

• Two negative pregnancy tests before starting treatment: Both tests must be performed in a medical setting (prescriber’s office or laboratory) with no home testing allowed for pre-treatment confirmation​

• Monthly negative pregnancy tests throughout treatment: As of the 2024 FDA-mandated changes, these monthly tests can be conducted in a medical setting or using home pregnancy tests, at the prescriber’s discretion​

• Two forms of contraception: Patients must use two effective forms of birth control simultaneously or commit to complete abstinence from sexual contact that could result in pregnancy, starting one month before treatment, during treatment, and for one month after stopping isotretinoin​

• Monthly comprehension questions: Before each prescription can be filled, patients must log into iPLEDGE and correctly answer questions demonstrating their understanding of the program requirements and the risks associated with isotretinoin​

• Seven-day prescription window: Patients have only 7 days from the date their pregnancy test specimen was collected to pick up their prescription from the pharmacy​

• Monthly office visits: Patients must see their prescriber monthly for evaluation, pregnancy testing, and prescription authorization​

Patients Who Cannot Get Pregnant

This category includes individuals assigned male at birth, those who have had a hysterectomy or oophorectomy, or those who are post-menopausal (with prescriber confirmation).​

Requirements for this category are less burdensome:

• No pregnancy testing required

• No birth control requirements

• Comprehension questions only at enrollment (not monthly)

• 30-day prescription window instead of the 7-day window

• Counseling documentation only at enrollment as of the 2024 FDA changes (previously required monthly)​

Important Note: Testosterone therapy is not considered an effective means of birth control, and patients on testosterone who retain reproductive potential must register as patients who can get pregnant.​

iPLEDGE Login Process: Step-by-Step Guide

Understanding the complete workflow from enrollment to monthly maintenance ensures smooth access to isotretinoin treatment.

Initial Enrollment Process

1. Consultation with dermatologist: Your dermatologist assesses your acne severity and determines if isotretinoin is appropriate for your condition​

2. Prescriber registration: Your doctor registers you in the iPLEDGE system, providing your demographic information and patient category​

3. Receive credentials: You receive your patient ID number and ID card from your prescriber​

4. Password delivery: Within 5-10 business days, you receive your password by mail (or can create one online after December 2021 system updates)​

5. Review educational materials: Study all patient education materials provided, including information about birth defects, side effects, and program requirements​

6. Sign informed consent: Complete and sign all required consent forms acknowledging your understanding of isotretinoin risks​

For Patients Who Can Get Pregnant: Pre-Treatment Steps

1. First pregnancy test: Complete an initial pregnancy test at a laboratory or medical facility—this begins your 30-day waiting period​

2. Wait 30 days: This mandatory waiting period ensures that any potential pregnancy is detected before treatment begins​

3. Second pregnancy test: Exactly 30 days after registration (not earlier, or it won’t count), complete your confirmatory pregnancy test​

4. Office visit: Two days after your second pregnancy test, return to your prescriber’s office to receive your first prescription​

5. Complete online questions: Before the pharmacy will dispense your medication, log into iPLEDGE to answer comprehension questions and enter your two forms of birth control​

6. Pharmacy pickup: Pick up your prescription within the 7-day window​

Monthly Login and Maintenance

Each month, patients who can get pregnant must follow this workflow:

1. Schedule labs: Get your monthly pregnancy test 25-35 days from your previous test (you have a flexible 5-day window before and after the 30-day mark)​

2. Prescriber confirmation: Your doctor logs into iPLEDGE to enter your negative pregnancy test result and confirm your monthly office visit​

3. Patient login: After your prescriber’s confirmation (usually 2 days after your pregnancy test), log into ipledgeprogram.com using your patient ID and password​

4. Answer comprehension questions: Complete the monthly questions about program requirements and contraception methods​

5. Confirm birth control: Enter your two forms of birth control, ensuring they match what your prescriber entered​

6. Receive authorization: Once completed successfully, the system generates a Risk Management Authorization (RMA) number that allows your pharmacy to dispense the medication​

7. Pharmacy verification: You can either provide your iPLEDGE ID number to the pharmacy or display your unique QR code available on your account​

8. Pickup within window: Collect your prescription within the 7-day window​

Patients who cannot get pregnant have a simpler monthly process, as they only need their prescriber to authorize the prescription and can pick it up within a 30-day window without monthly online tasks.​

Recent Updates and Changes to iPLEDGE (2021-2025)

The iPLEDGE program has undergone significant modifications in recent years, aimed at reducing administrative burdens while maintaining safety standards.

December 2021 System Update

On December 13, 2021, the iPLEDGE program implemented major changes including a new digital platform administered by Syneos Health. Key changes included:​

• Patient risk categories reduced from three to two

• New gender-neutral terminology (“patients who can get pregnant” vs. “patients who cannot get pregnant”)

• QR code functionality allowing patients to present a unique code at pharmacies instead of their ID number​

• New website platform requiring users to create new passwords and confirm patient categories​

Case Study in Systemic Failure: The 2021 IT Debacle

The December 2021 transition represents a critical case study in how platform migration failures can create cascading operational failures across an integrated healthcare system. From an information technology perspective, the rollout exhibited multiple fundamental failures in change management, load testing, user acceptance testing, and disaster recovery planning.​

The technical problems manifested in several critical ways:

• Server capacity failures: The website experienced complete crashes and prolonged downtime during peak usage hours, suggesting inadequate load balancing and server provisioning​

• Authentication system failures: Users reported inability to log in despite correct credentials, indicating database migration or authentication service failures​

• Call center infrastructure collapse: Wait times exceeded 177 minutes in some reported cases, with some patients unable to reach support after hours on hold. The contact center infrastructure clearly lacked the scalability to handle the surge in support requests generated by the platform failures.​

• Data migration issues: Some users found their historical data missing or incorrectly transferred, suggesting incomplete or improperly validated data migration processes​

These disruptions had severe real-world consequences: thousands of patients had their acne treatment interrupted for days or weeks, prescribers spent excessive time attempting to help patients access the system rather than providing clinical care, and pharmacies were unable to dispense authorized prescriptions due to system verification failures.

The FDA acknowledged the severity of the situation and held multiple emergency meetings with IPMG to develop interim solutions. However, IPMG initially indicated that proposed FDA solutions were “not feasible to quickly implement,” raising questions about the system’s architectural flexibility and the vendor’s technical capabilities. The fact that a supposedly mission-critical healthcare IT system lacked adequate failover mechanisms or rollback capabilities represents a fundamental failure in enterprise IT governance.​

This episode demonstrates how poorly executed IT modernization in healthcare regulation can create systemic access barriers that directly contradict the policy objectives of the underlying program. The 2021 transition transformed iPLEDGE from merely an administratively burdensome system into an actively failing technical infrastructure that prevented medication access regardless of clinical appropriateness or regulatory compliance.​

March 2023 FDA Advisory Committee Recommendations

In March 2023, the FDA convened joint meetings of the Drug Safety and Risk Management Advisory Committee and the Dermatologic and Ophthalmic Drugs Advisory Committee to address ongoing concerns about the iPLEDGE program. Following testimony from patients, dermatologists, and advocacy groups, the committees voted on several key recommendations:​

• 17 of 22 members voted against continuing the 19-day lockout period for patients who miss their initial prescription window​

• 10 of 22 members voted to require counseling documentation only at enrollment for patients who cannot get pregnant (not monthly)​

November 2023 FDA Mandated Changes

On November 30, 2023, the FDA issued a letter requiring isotretinoin manufacturers to implement five major modifications to the iPLEDGE REMS program within six months:​

1. Remove CLIA-certified laboratory requirement: Pregnancy tests no longer need to be performed in specially certified Clinical Laboratory Improvement Amendments (CLIA) laboratories, though pre-treatment tests must still be done in medical settings​

2. Allow home pregnancy testing during treatment: Prescribers can now authorize home pregnancy tests for monthly monitoring during and after isotretinoin treatment, facilitating telemedicine options​

3. Eliminate the 19-day lockout: Patients who miss their 7-day prescription window no longer face a mandatory 19-day waiting period before retrying. They can immediately repeat a pregnancy test to start a new authorization window​

4. Reduce counseling documentation for patients who cannot get pregnant: Monthly counseling documentation is no longer required; it’s now only mandated at enrollment​

5. Revise pregnancy registry requirements: Remove the objective to document pregnancy and fetal outcomes data collection, streamlining the registry process​

Implementation Timeline

These changes require up to a year or more for full implementation, as manufacturers must submit their modifications to the FDA for review (typically a 6-month review period), followed by technical implementation by the system vendor. As of October 2025, these improvements are in various stages of implementation.​

iPLEDGE Requirements Comparison Table

Benefits of the iPLEDGE Program

Despite its complexity and administrative challenges, the iPLEDGE program provides several important benefits:

Patient Safety Protection

The program ensures that patients fully understand the serious risks associated with isotretinoin before and during treatment. Monthly pregnancy testing and contraception verification create multiple layers of protection against fetal exposure.​

Prescriber Liability Protection

Healthcare providers who comply with all iPLEDGE requirements are protected from liability related to isotretinoin-associated birth defects. The program creates documented evidence that all safety protocols were followed.​

Access to Highly Effective Treatment

Without a structured risk management program, isotretinoin might not be available at all due to its teratogenic risks. The iPLEDGE program allows patients with severe acne to access this life-changing medication safely.​

Standardized Safety Protocols

The program establishes uniform requirements across all prescribers, pharmacies, and patients, ensuring consistent safety standards nationwide.​

Challenges and Criticisms of iPLEDGE

While the iPLEDGE program serves important safety objectives, it has faced substantial criticism since its inception:

Cost of Inefficiency: Administrative Burden on Practices

The program imposes significant time and paperwork requirements on prescribers, particularly for solo and small practices. Research demonstrates the magnitude of this burden: in a 2022 survey of over 510 board-certified dermatologists across the United States, more than 30% reported they had chosen not to prescribe isotretinoin to appropriate patients at some point specifically because of the administrative burden of iPLEDGE requirements. This finding is particularly pronounced among dermatologists younger than 46 years, suggesting that the program is actively deterring the next generation of clinicians from prescribing this highly effective medication.​

The economic impact extends beyond missed prescribing opportunities. Many dermatologists report that iPLEDGE compliance “is costly in both time and money”, with the program’s strict requirements requiring dedicated staff time for patient education, system navigation, documentation, and troubleshooting. Following the introduction of iPLEDGE in 2006, there was a 29% decrease in isotretinoin prescriptions nationwide, despite the medication’s unrivaled efficacy. This dramatic reduction suggests that the administrative burden created by iPLEDGE has restricted access to effective treatment for hundreds of thousands of patients with severe acne.​

Patient Access Barriers and Disproportionate Impact

The strict timelines and requirements create barriers, particularly for patients from lower socioeconomic backgrounds who may have difficulty scheduling monthly appointments, affording transportation to testing facilities, or taking time off work or school. Research quantifies these access barriers: a comprehensive 2019 study of 418 patients at two academic medical centers in Boston found that 43.5% of non-white patients ended their isotretinoin course early compared to 30.1% of white patients ($p=0.010$). Non-white patients were also significantly more likely to experience medication interruptions and achieve sub-optimal cumulative doses of isotretinoin.​

When examining reasons for treatment delays and interruptions, iPLEDGE-related logistics were cumulatively the most common specified cause, including computer issues navigating the website (28.9% of delays), missed pickup windows (15.8-22.9% of delays and interruptions), and missed or delayed appointments and pregnancy tests (18.4-25.7%). Overall, the study documented that 36.8% of patients experienced early termination of their treatment course, with loss to follow-up accounting for 53.2% of these early terminations.​

The financial burden on patients is substantial. Studies document that most pediatric patients incurred costs greater than $25 per monthly office visit, with the average pediatric patient missing 3 hours of school each month due to required appointments. For patients who can get pregnant, the monthly out-of-pocket expense for pregnancy tests often does not fall under insurance coverage, creating an ongoing financial barrier throughout treatment. These cumulative costs—transportation, time away from work or school, pregnancy test expenses, and office visit copayments—create what researchers describe as “unjustifiable increased cost of treatment” that disproportionately impacts patients from lower socioeconomic backgrounds.​

Effectiveness Questions

Despite its burdens, the iPLEDGE program’s effectiveness remains questionable. A 2011 study found that after iPLEDGE implementation, the unadjusted rate of fetal exposure decreased from 3.11 to 2.67 per 1,000 treatment courses—a reduction that was not statistically significant ($p=0.69$). More recent data shows that 200-300 pregnancies occur in individuals taking isotretinoin every year, maintaining rates of approximately 2.7 pregnancies exposed to isotretinoin per 1,000 treatment courses. These persistent pregnancy rates raise fundamental questions about whether the program’s substantial burdens are justified by its outcomes.​

Notably, abstinence—which accounts for approximately 46.2% of primary contraception methods selected by patients in iPLEDGE monthly interactions—has been cited as the second most common contraceptive method among isotretinoin patients who became pregnant. This finding suggests that the program’s acceptance of abstinence as a birth control strategy may contribute to its limited effectiveness.​

Disproportionate Impact on Low-Risk Populations

Male patients and females who cannot become pregnant face the same enrollment requirements and administrative processes as patients of reproductive potential, despite having zero risk of causing fetal exposure. This creates what critics argue is an inequitable and unnecessarily burdensome system that fails to differentiate regulatory requirements based on actual risk profiles. Prior to the 2024 changes, these patients were required to complete monthly counseling documentation and face the same strict compliance requirements as patients who can get pregnant.​

Privacy and Ethical Concerns

The requirement to report contraceptive use and pregnancy status to a government-affiliated database raises significant privacy concerns, particularly for adolescent patients. The iPLEDGE program often represents many patients’ first introduction to contraception, yet studies show that few clinicians provide comprehensive information about highly effective reversible contraceptives such as intrauterine devices or subdermal implants during iPLEDGE counseling. Most counseling focuses on oral contraceptives, and research indicates that “the iPLEDGE program increases anxiety about isotretinoin more than it helps women feel protected from the teratogenic risks”.​

Prescription Fill Failure Rates

The cumulative effect of these barriers manifests in alarming prescription fill rates. The FDA has indicated that approximately 40% of isotretinoin prescriptions written over the course of one year were denied due to failure to comply with iPLEDGE requirements. An innovative patient support program designed to address adherence challenges documented that their intervention increased prescription fill rates to 93%, compared to the baseline 60% fill rate under standard iPLEDGE procedures. This 33 percentage point improvement demonstrates that the current system’s complexity, rather than patient willingness or clinical appropriateness, drives much of the prescription denial rate.​

iPLEDGE Contact Information and Support Resources

iPLEDGE REMS Contact Center

• Phone: 1-866-495-0654

• Hours: Normal business hours (Monday-Friday, typically 8:00 AM – 4:30 PM ET)

• Services: Account access assistance, password resets, enrollment questions, prescription authorization issues​

iPLEDGE Mailing Address

The iPLEDGE REMS
2083 Pinecrest Dr.
Morgantown, West Virginia 26505
United States​

Website Resources

• Official portal: ipledgeprogram.com​

• Enrollment forms: Available through the website’s “Enroll | Login” section​

• Patient guides: Downloadable educational materials for different patient categories​

• Prescriber resources: Enrollment forms, best practices guides, and troubleshooting tips​

Additional Support

Prescribers can send login links directly to patients experiencing access difficulties through the “Manage Patients” page. The FDA also maintains updated information about iPLEDGE on its website at fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/ipledge-risk-evaluation-and-mitigation-strategy-rems.​

Tips for Successful iPLEDGE Navigation

For Patients

1. Mark your calendar: Track your pregnancy test dates, office visits, and prescription windows carefully to avoid missing critical deadlines​

2. Set up email notifications: Ensure your email address is current in the system so you receive important communications from iPLEDGE​

3. Use desktop computers: The iPLEDGE website works best on laptop or desktop computers using Chrome or Firefox browsers rather than tablets, smartphones, or Internet Explorer​

4. Disable pop-up blockers: Browser pop-up blockers can interfere with the iPLEDGE website functionality​

5. Save your QR code: Take a screenshot of your unique QR code from your iPLEDGE account to show at the pharmacy​

6. Call during off-peak hours: If you need to contact the call center, avoid Mondays and try calling later in the week or outside peak business hours​

7. Keep documentation: Maintain records of your pregnancy test dates, office visits, and prescription authorizations​

For Prescribers

1. Count days carefully: The iPLEDGE calendar functionality was removed in the 2021 update, so manually track the 30-day intervals for patients who can get pregnant​

2. Use paper consent forms: Having patients sign paper copies that can be scanned during online registration streamlines the enrollment process​

3. Send login links proactively: Use the “SEND LOGIN LINK” feature to help patients access their accounts without calling the busy call center​

4. Educate staff thoroughly: Ensure all designees understand the system requirements and have their own access credentials​

5. Schedule conservatively: Schedule patients for follow-up visits at least 31 days from their last update to ensure compliance with the 30-day minimum requirement​

Future of the iPLEDGE Program

The American Academy of Dermatology Association (AADA) continues to advocate for additional improvements to the iPLEDGE program beyond the 2024 FDA-mandated changes. Ongoing advocacy efforts focus on:​

• Further streamlining requirements for patients who cannot get pregnant

• Improving website functionality and user experience

• Increasing transparency in program administration

• Recognizing highly effective forms of contraception

• Shortening the 30-day waiting period before treatment initiation​

The AADA has requested multi-stakeholder meetings with IPMG, the FDA, patients, and physicians to develop long-term solutions, though IPMG has not yet agreed to this format. Congressional representatives have also received input from constituents frustrated with the program, potentially leading to legislative pressure for reforms.​

As telemedicine becomes increasingly prevalent, the recent allowance for home pregnancy testing represents an important step toward making isotretinoin treatment more accessible while maintaining safety standards.​

Conclusion

The iPLEDGE login portal and program requirements represent a complex but necessary framework for managing the serious risks associated with isotretinoin therapy. While the program faces ongoing criticism regarding administrative burdens and access barriers—with data showing that 40% of prescriptions are denied due to compliance failures, 36.8% of patients terminate treatment early, and 30% of dermatologists avoid prescribing isotretinoin specifically due to iPLEDGE burdens—it serves the critical function of preventing devastating birth defects that can result from isotretinoin exposure during pregnancy.

The December 2021 system transition demonstrated how technical failures in healthcare IT infrastructure can create systemic access crises, transforming regulatory compliance from an administrative challenge into an active barrier to medication access. This episode underscores the need for robust IT governance, comprehensive testing, and disaster recovery planning in mission-critical healthcare systems.

Recent FDA-mandated changes demonstrate responsiveness to stakeholder concerns and a willingness to evolve the program to reduce unnecessary burdens while maintaining safety standards. The elimination of the 19-day lockout, allowance for home pregnancy testing during treatment, and reduction of counseling documentation requirements for patients who cannot get pregnant represent meaningful improvements that will benefit thousands of patients seeking effective treatment for severe acne.

Understanding how to successfully navigate the iPLEDGE login process, comply with program requirements, and utilize available support resources enables patients, prescribers, and pharmacies to work together effectively. By following the guidelines outlined in this comprehensive guide, all stakeholders can ensure safe, compliant access to isotretinoin treatment while minimizing disruptions and delays.

For the most current information about iPLEDGE requirements and updates, always consult the official iPLEDGE website at ipledgeprogram.com or contact the iPLEDGE REMS Contact Center at 1-866-495-0654. If you experience persistent difficulties with the program, don’t hesitate to reach out to your healthcare provider or the iPLEDGE support team for assistance.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with your healthcare provider regarding isotretinoin treatment and iPLEDGE program requirements specific to your situation. The information presented reflects program details as of October 2025 and may be subject to change as the FDA and IPMG continue to modify the iPLEDGE REMS program.

Suggested reads:

• RealEstateU Login: Comprehensive Guide and Platform Profile
• Complete MyPhoenix Login & Navigation Guide for UoPX Students